Table of Contents Author Guidelines Submit a Manuscript
Journal of Nutrition and Metabolism
Volume 2011 (2011), Article ID 981315, 8 pages
http://dx.doi.org/10.1155/2011/981315
Review Article

FGF21 as an Endocrine Regulator in Lipid Metabolism: From Molecular Evolution to Physiology and Pathophysiology

Department of Genetic Biochemistry, Kyoto University Graduate School of Pharmaceutical Sciences, Sakyo, Kyoto 606-8501, Japan

Received 14 November 2010; Accepted 5 January 2011

Academic Editor: Chandan Prasad

Copyright © 2011 Yusuke Murata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Gospodarowicz, “Purification of a fibroblast growth factor from bovine pituitary,” Journal of Biological Chemistry, vol. 250, no. 7, pp. 2515–2520, 1975. View at Google Scholar · View at Scopus
  2. D. Gospodarowicz, H. Bialecki, and G. Greenburg, “Purification of the fibroblast growth factor activity from bovine brain,” Journal of Biological Chemistry, vol. 253, no. 10, pp. 3736–3743, 1978. View at Google Scholar · View at Scopus
  3. N. Itoh and D. M. Ornitz, “Evolution of the Fgf and Fgfr gene families,” Trends in Genetics, vol. 20, no. 11, pp. 563–569, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. N. Itoh and D. M. Ornitz, “Functional evolutionary history of the mouse Fgf gene family,” Developmental Dynamics, vol. 237, no. 1, pp. 18–27, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. N. Itoh, “The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease,” Biological and Pharmaceutical Bulletin, vol. 30, no. 10, pp. 1819–1825, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Itoh and D. M. Ornitz, “Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease,” Journal of Biochemistry, vol. 149, no. 2, pp. 121–130, 2011. View at Google Scholar
  7. A. Beenken and M. Mohammadi, “The FGF family: biology, pathophysiology and therapy,” Nature Reviews Drug Discovery, vol. 8, no. 3, pp. 235–253, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. M. Goldfarb, “Fibroblast growth factor homologous factors: evolution, structure, and function,” Cytokine and Growth Factor Reviews, vol. 16, no. 2, pp. 215–220, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. M. Goldfarb, J. Schoorlemmer, A. Williams et al., “Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage-gated sodium channels,” Neuron, vol. 55, no. 3, pp. 449–463, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. M. Xiao, L. Xu, F. Laezza, K. Yamada, S. Feng, and D. M. Ornitz, “Impaired hippocampal synaptic transmission and plasticity in mice lacking fibroblast growth factor 14,” Molecular and Cellular Neuroscience, vol. 34, no. 3, pp. 366–377, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. H. Kurosu and M. Kuro-O, “Endocrine fibroblast growth factors as regulators of metabolic homeostasis,” BioFactors, vol. 35, no. 1, pp. 52–60, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. A. Kharitonenkov, “FGFs and metabolism,” Current Opinion in Pharmacology, vol. 9, no. 6, pp. 805–810, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. N. Itoh, “Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease,” Cell and Tissue Research, vol. 342, no. 1, pp. 1–11, 2010. View at Publisher · View at Google Scholar · View at PubMed
  14. A. Kharitonenkov, “FGFs and metabolism,” Current Opinion in Pharmacology, vol. 9, no. 6, pp. 805–810, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. M. S. Razzaque, “The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis,” Nature Reviews Endocrinology, vol. 5, no. 11, pp. 611–619, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. A. Kharitonenkov and A. B. Shanafelt, “Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases,” BioDrugs, vol. 22, no. 1, pp. 37–44, 2008. View at Google Scholar · View at Scopus
  17. A. Kharitonenkov and A. B. Shanafelt, “FGF21: a novel prospect for the treatment of metabolic diseases,” Current Opinion in Investigational Drugs, vol. 10, no. 4, pp. 359–364, 2009. View at Google Scholar · View at Scopus
  18. S. A. Kliewer and D. J. Mangelsdorf, “Fibroblast growth factor 21: from pharmacology to physiology,” American Journal of Clinical Nutrition, vol. 91, no. 1, pp. 254S–257S, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. D. Cuevas-Ramos, P. Almeda-Valdes, C. A. Aguilar-Salinas, G. Cuevas-Ramos, A. A. Cuevas-Sosa, and F. J. Gomez-Perez, “The role of fibroblast growth factor 21 (FGF21) on energy balance, glucose and lipid metabolism,” Current Diabetes Reviews, vol. 5, no. 4, pp. 216–220, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Rydén, “Fibroblast growth factor 21: an overview from a clinical perspective,” Cellular and Molecular Life Sciences, vol. 66, no. 13, pp. 2067–2073, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. T. Nishimura, Y. Nakatake, M. Konishi, and N. Itoh, “Identification of a novel FGF, FGF-21, preferentially expressed in the liver,” Biochimica et Biophysica Acta, vol. 1492, no. 1, pp. 203–206, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Kharitonenkov, T. L. Shiyanova, A. Koester et al., “FGF-21 as a novel metabolic regulator,” Journal of Clinical Investigation, vol. 115, no. 6, pp. 1627–1635, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. T. Inagaki, P. Dutchak, G. Zhao et al., “Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21,” Cell Metabolism, vol. 5, no. 6, pp. 415–425, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. M. K. Badman, P. Pissios, A. R. Kennedy, G. Koukos, J. S. Flier, and E. Maratos-Flier, “Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states,” Cell Metabolism, vol. 5, no. 6, pp. 426–437, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. R. Goetz, A. Beenken, O. A. Ibrahimi et al., “Molecular insights into the Klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members,” Molecular and Cellular Biology, vol. 27, no. 9, pp. 3417–3428, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. X. Zhang, O. A. Ibrahimi, S. K. Olsen, H. Umemori, M. Mohammadi, and D. M. Ornitz, “Receptor specificity of the fibroblast growth factor family: the complete mammalian FGF family,” Journal of Biological Chemistry, vol. 281, no. 23, pp. 15694–15700, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. Y. Satou, K. S. Imai, and N. Satoh, “Fgf genes in the basal chordate Ciona intestinalis,” Development Genes and Evolution, vol. 212, no. 9, pp. 432–438, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. N. Nikitina, M. Bronner-Fraser, and T. Sauka-Spengler, “The sea lamprey Petromyzon marinus: a model for evolutionary and developmental biology,” Cold Spring Harbor Protocols, vol. 1, pp. 405–429, 2009. View at Google Scholar
  29. H. Ellegren, “The avian genome uncovered,” Trends in Ecology and Evolution, vol. 20, no. 4, pp. 180–186, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. K. F. Tacer, A. L. Bookout, X. Ding et al., “Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse,” Molecular Endocrinology, vol. 24, no. 10, pp. 2050–2064, 2010. View at Publisher · View at Google Scholar · View at PubMed
  31. J. S. Moyers, T. L. Shiyanova, F. Mehrbod et al., “Molecular determinants of FGF-21 activity—synergy and cross-talk with PPARγ signaling,” Journal of Cellular Physiology, vol. 210, no. 1, pp. 1–6, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. Y. Hotta, H. Nakamura, M. Konishi et al., “Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver,” Endocrinology, vol. 150, no. 10, pp. 4625–4633, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. K. Mai, J. Andres, K. Biedasek et al., “Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21,” Diabetes, vol. 58, no. 7, pp. 1532–1538, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. D. D. Moore, “Sister act,” Science, vol. 316, no. 5830, pp. 1436–1438, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. M. Kuro-o, “Endocrine FGFs and Klothos: emerging concepts,” Trends in Endocrinology and Metabolism, vol. 19, no. 7, pp. 239–245, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. M. D. L. Chau, J. Gao, Q. Yang, Z. Wu, and J. Gromada, “Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1α pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 28, pp. 12553–12558, 2010. View at Publisher · View at Google Scholar · View at PubMed
  37. S. Kersten, J. Seydoux, J. M. Peters, F. J. Gonzalez, B. Desvergne, and W. Wahli, “Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting,” Journal of Clinical Investigation, vol. 103, no. 11, pp. 1489–1498, 1999. View at Google Scholar · View at Scopus
  38. T. C. Leone, C. J. Weinheimer, and D. P. Kelly, “A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 13, pp. 7473–7478, 1999. View at Publisher · View at Google Scholar
  39. C. Gälman, T. Lundåsen, A. Kharitonenkov et al., “The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man,” Cell Metabolism, vol. 8, no. 2, pp. 169–174, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. C. Christodoulides, P. Dyson, D. Sprecher, K. Tsintzas, and F. Karpe, “Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 9, pp. 3594–3601, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. M. K. Badman, A. Koester, J. S. Flier, A. Kharitonenkov, and E. Maratos-Flier, “Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis,” Endocrinology, vol. 150, no. 11, pp. 4931–4940, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. J. L. Estall, J. L. Ruas, C. S. Choi et al., “PGC-1α negatively regulates hepatic FGF21 expression by modulating the heme/Rev-Erbα axis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 52, pp. 22510–22515, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. M. J. Potthoff, T. Inagaki, S. Satapati et al., “FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 26, pp. 10853–10858, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. J. P. Thissen, L. E. Underwood, and J. M. Ketelslegers, “Regulation of insulin-like growth factor-I in starvation and injury,” Nutrition Reviews, vol. 57, no. 6, pp. 167–176, 1999. View at Google Scholar · View at Scopus
  45. T. Inagaki, V. Y. Lin, R. Goetz, M. Mohammadi, D. J. Mangelsdorf, and S. A. Kliewer, “Inhibition of growth hormone signaling by the fasting-induced hormone FGF21,” Cell Metabolism, vol. 8, no. 1, pp. 77–83, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. R. G. Melvin and M. T. Andrews, “Torpor induction in mammals: recent discoveries fueling new ideas,” Trends in Endocrinology and Metabolism, vol. 20, no. 10, pp. 490–498, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. S. Chikahisa, K. Tominaga, T. Kawai et al., “Bezafibrate, a peroxisome proliferator-activated receptors agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice,” Endocrinology, vol. 149, no. 10, pp. 5262–5271, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. K. Oishi, K. Sakamoto, M. Konishi, Y. Murata, N. Itoh, and H. Sei, “FGF21 is dispensable for hypothermia induced by fasting in mice,” Neuroendocrinology Letters, vol. 31, no. 2, pp. 198–202, 2010. View at Google Scholar · View at Scopus
  49. N. Turner and R. Grose, “Fibroblast growth factor signalling: from development to cancer,” Nature Reviews Cancer, vol. 10, no. 2, pp. 116–129, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. M. Kuro-o, Y. Matsumura, H. Aizawa et al., “Mutation of the mouse klotho gene leads to a syndrome resembling ageing,” Nature, vol. 390, no. 6655, pp. 45–51, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. S. Ito, S. Kinoshita, N. Shiraishi et al., “Molecular cloning and expression analyses of mouse βklotho, which encodes a novel Klotho family protein,” Mechanisms of Development, vol. 98, no. 1-2, pp. 115–119, 2000. View at Publisher · View at Google Scholar · View at Scopus
  52. I. Urakawa, Y. Yamazaki, T. Shimada et al., “Klotho converts canonical FGF receptor into a specific receptor for FGF23,” Nature, vol. 444, no. 7120, pp. 770–774, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. S. Ito, T. Fujimori, A. Furuya, J. Satoh, Y. Nabeshima, and Y. I. Nabeshima, “Impaired negative feedback suppression of bile acid synthesis in mice lacking βKlotho,” Journal of Clinical Investigation, vol. 115, no. 8, pp. 2202–2208, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. C. Yu, F. Wang, M. Kan et al., “Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4,” Journal of Biological Chemistry, vol. 275, no. 20, pp. 15482–15489, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Inagaki, M. Choi, A. Moschetta et al., “Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis,” Cell Metabolism, vol. 2, no. 4, pp. 217–225, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. H. Kurosu, M. Choi, Y. Ogawa et al., “Tissue-specific expression of βklotho and Fibroblast Growth Factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21,” Journal of Biological Chemistry, vol. 282, no. 37, pp. 26687–26695, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. Y. Ogawa, H. Kurosu, M. Yamamoto et al., “βKlotho is required for metabolic activity of fibroblast growth factor 21,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 18, pp. 7432–7437, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. A. Kharitonenkov, J. D. Dunbar, H. A. Bina et al., “FGF-21/FGF-21 receptor interaction and activation is determined by βKlotho,” Journal of Cellular Physiology, vol. 215, no. 1, pp. 1–7, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. M. Suzuki, Y. Uehara, K. Motomura-Matsuzaka et al., “βklotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c,” Molecular Endocrinology, vol. 22, no. 4, pp. 1006–1014, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. K. I. Tomiyama, R. Maeda, I. Urakawa et al., “Relevant use of Klotho in FGF19 subfamily signaling system in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 4, pp. 1666–1671, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. G. Morris-Stiff and A. E. Feldstein, “Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice,” Journal of Hepatology, vol. 53, no. 5, pp. 795–796, 2010. View at Publisher · View at Google Scholar · View at PubMed
  62. E. Bugianesi, S. Moscatiello, M. F. Ciaravella, and G. Marchesini, “Insulin resistance in nonalcoholic fatty liver disease,” Current Pharmaceutical Design, vol. 16, no. 17, pp. 1941–1951, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Yilmaz, F. Eren, O. Yonal et al., “Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease,” European Journal of Clinical Investigation, vol. 40, no. 10, pp. 887–892, 2010. View at Publisher · View at Google Scholar · View at PubMed
  64. J. Dushay, P. C. Chui, G. S. Gopalakrishnan et al., “Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease,” Gastroenterology, vol. 139, no. 2, pp. 456–463, 2010. View at Publisher · View at Google Scholar · View at PubMed
  65. H. Li, Q. Fang, F. Gao et al., “Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride,” Journal of Hepatology, vol. 53, no. 5, pp. 934–940, 2010. View at Publisher · View at Google Scholar · View at PubMed
  66. W. W. Chen, L. Li, G. Y. Yang et al., “Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus,” Experimental and Clinical Endocrinology and Diabetes, vol. 116, no. 1, pp. 65–68, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. X. Zhang, D. C. Y. Yeung, M. Karpisek et al., “Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans,” Diabetes, vol. 57, no. 5, pp. 1246–1253, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. A. O. Chavez, M. Molina-Carrion, M. A. Abdul-Ghani, F. Folli, R. A. DeFronzo, and D. Tripathy, “Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance,” Diabetes Care, vol. 32, no. 8, pp. 1542–1546, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. M. Mraz, M. Bartlova, Z. Lacinova et al., “Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity,” Clinical Endocrinology, vol. 71, no. 3, pp. 369–375, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. S. Stein, H. Stepan, J. Kratzsch et al., “Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia,” Metabolism, vol. 59, no. 1, pp. 33–37, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. B. Matuszek, M. Lenart-Lipińska, D. Duma, J. Solski, and A. Nowakowski, “Evaluation of concentrations of FGF-21—a new adipocytokine in type 2 diabetes,” Endokrynologia Polska, vol. 61, no. 1, pp. 50–54, 2010. View at Google Scholar · View at Scopus
  72. F. M. Fisher, P. C. Chui, P. J. Antonellis et al., “Obesity is a fibroblast growth factor 21 (FGF21)-resistant state,” Diabetes, vol. 59, no. 11, pp. 2781–2789, 2010. View at Publisher · View at Google Scholar · View at PubMed
  73. H. Li, Y. Bao, A. Xu et al., “Serum fibroblast growth factor 21 is associated with adverse lipid profiles and γ-glutamyltransferase but not insulin sensitivity in Chinese subjects,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 6, pp. 2151–2156, 2009. View at Publisher · View at Google Scholar · View at PubMed
  74. V. Durovcová, J. Marek, V. Hána et al., “Plasma concentrations of fibroblast growth factors 21 and 19 in patients with Cushing's syndrome,” Physiological Research, vol. 59, no. 3, pp. 415–422, 2010. View at Google Scholar
  75. F. Villarroya, P. Domingo, and M. Giralt, “Lipodystrophy in HIV 1-infected patients: lessons for obesity research,” International Journal of Obesity, vol. 31, no. 12, pp. 1763–1776, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. P. Domingo, J. M. Gallego-Escuredo, J. C. Domingo et al., “Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients,” AIDS, vol. 24, no. 17, pp. 2629–2637, 2010. View at Publisher · View at Google Scholar · View at PubMed
  77. S. Stei, A. Bachmann, U. Lössner et al., “Serum levels of the adipokine FGF21 depend on renal function,” Diabetes Care, vol. 32, no. 1, pp. 126–128, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. S. H. Han, S. H. Choi, B. J. Cho et al., “Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis,” Metabolism, vol. 59, no. 11, pp. 1656–1562, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus